Clinical Trial Update: Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (MIGRANT) is evaluating the safety and feasibility of fecal microbiota transplant in stage II-III non-small cell lung cancer patients, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Fecal microbiota transplant (fecal microbiota transplant)

Snippet

Sponsor: Fundación GECP | Conditions: Non Small Cell Lung Cancer, Respiratory Tract Neoplasm | Phase 2 | Status: NOT_YET_RECRUITING